Երկիր: Կանադա
Լեզու: անգլերեն
Աղբյուրը: Health Canada
TOLTERODINE TARTRATE
MYLAN PHARMACEUTICALS ULC
G04BD07
TOLTERODINE
2MG
CAPSULE (EXTENDED RELEASE)
TOLTERODINE TARTRATE 2MG
ORAL
30/100
Prescription
Antimuscarinics
Active ingredient group (AIG) number: 0135202002; AHFS:
CANCELLED POST MARKET
2022-02-14
_ _ _MYLAN-TOLTETODINE ER_ _ (tolterodine L-tartrate extended release capsules) Product Monograph _ _Page 1 of _ 35 _ _ PRODUCT MONOGRAPH PR MYLAN-TOLTERODINE ER (TOLTERODINE L-TARTRATE EXTENDED RELEASE CAPSULES) 2 MG AND 4 MG CAPSULES ANTICHOLINERGIC - ANTISPASMODIC AGENT MYLAN PHARMACEUTICALS ULC 85 ADVANCE ROAD, ETOBICOKE ON, M8Z 2S6 DATE OF PREPARATION: APRIL 28, 2015 SUBMISSION CONTROL NO: 147332, 183925 _ _ _MYLAN-TOLTETODINE ER_ _ (tolterodine L-tartrate extended release capsules) Product Monograph _ _Page 2 of _ 35 _ _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION........................................................................ 3 SUMMARY PRODUCT INFORMATION .............................................................................................. 3 INDICATIONS AND CLINICAL USE .................................................................................................... 3 CONTRAINDICATIONS ......................................................................................................................... 4 WARNINGS AND PRECAUTIONS........................................................................................................ 4 ADVERSE REACTIONS ......................................................................................................................... 7 DRUG INTERACTIONS .......................................................................................................................... 9 DOSAGE AND ADMINISTRATION .................................................................................................... 11 OVERDOSAGE ...................................................................................................................................... 12 ACTION AND CLINICAL PHARMACOLOGY .................................................................................. 13 STORAGE AND STABILITY................................................................................................................ 15 SPECIAL HANDLING INSTRUCTIONS ... Կարդացեք ամբողջական փաստաթուղթը